Fighting Fire with Fire: Rekindling the Bevacizumab Debate
Menées respectivement sur 1 206 et 1 948 patientes atteintes d'un cancer métastatique du sein, ces deux études évaluent l'ajout de bevacizumab à une chimiothérapie néoadjuvante
The results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 trial1 and the GeparQuinto (GBG44) trial,2 both of which are reported in this issue of the Journal, are particularly timely given the definitive announcement by the Food and Drug Administration (FDA) on November 18, 2011, revoking approval of bevacizumab in combination with paclitaxel for the treatment of metastatic breast cancer (see www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf). Bevacizumab, a monoclonal antibody against circulating vascular endothelial growth factor A, was granted accelerated FDA approval in 2008 for the first-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer. Initial approval . . .
New England Journal of Medicine , éditorial, 2011